WHO ICTRP trial
A 52-week Treatment, Multi-center, Randomized, Double-blind, Double Dummy…
JPRN-jRCT2080222133 · Japan Primary Registries Network (JPRN)
Key facts
| Trial ID | JPRN-jRCT2080222133 |
|---|---|
| Public title | A 52-week Treatment, Multi-center, Randomized, Double-blind, Double Dummy, Parallel-group, Active Controlled Study to Compare the Effect of QVA149 (Indacaterol Maleate / Glycopyrronium Bromide) With Salmeterol/Futicasone on the Rate of Exacerbations in Subjects With Moderate to Very Severe COPD. |
| Scientific title | A 52-week Treatment, Multi-center, Randomized, Double-blind, Double Dummy, Parallel-group, Active Controlled Study to Compare the Effect of QVA149 (Indacaterol Maleate / Glycopyrronium Bromide) With Salmeterol/Futicasone on the Rate of Exacerbations in Subjects With Moderate to Very Severe COPD. |
| Primary sponsor | Novartis Pharma K.K. |
| Registry | Japan Primary Registries Network (JPRN) |
| Study type | Interventional |
| Phase | 3 |
| Conditions | Chronic Obstructive Pulmonary Disease ( COPD) |
| Interventions | investigational material(s) Generic name etc : QVA149 (Indacaterol Maleate / Glycopyrronium Bromide) INN of investigational material : Therapeutic category code : 225 Bronchodilators Dosage and Administration for Investigational material… |
| Registration date | Jan 7, 2013 |
| Target size | 3332 |
| Secondary IDs | JapicCTI-132179 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: